Tumour Markers in Gynaecologic Oncology

References

• Bagshawe KD. Treatment of trophoblastic tumours. Ann Acad Med 1976; 5: 273
   Google Scholar
• Franke H R, Risse K J, Kenemans P, et al. Plasma human chorionic gonadotropin disappearance in hyatidiform mole: A central registry report from the Netherlands. Obstet Gynecol 1983; 62: 467
   PubMed Web of Science ®Google Scholar
• Dosogne-Guerin M, Stolarczyk A, Borkowski A. Prospective study of the alpha and beta subunits of human chorionic gonadotropin in the blood of patients with various benign and malignant conditions. Eur J Cancer 1978; 14: 525
   PubMed Web of Science ®Google Scholar
• Khazaeli M B, Hedayat M M, Hatch KD, et al. Radioimmunoaasay for free beta hCG assay for early detection of persistant trophoblastic disease. Am J Obstet Gynecol 1986; 155: 320
   PubMed Web of Science ®Google Scholar
• Young R H, Scully RE. Placental site trophoblastic tumour: Current status. Clin Obstet Gynecol 1984; 27: 248
   PubMed Web of Science ®Google Scholar
• Kato H, Torigoe T. Radioimmunoassay for tumor antigen of human cervical squamous cell carcinoma. Cancer 1977; 40: 1621
   PubMed Web of Science ®Google Scholar
• Senikjian E K, Young J M, Weiser PA, et al. An evaluation of squamous cell carcinoma antigen in patients with cervical squamous cell carcinoma. Am J Obstet Gynecol 1987; 157: 433
   PubMed Web of Science ®Google Scholar
• Scambia G, Panici P B, Baiocchi G, et al. The value of squamous cell carcinoma antigen in patients with locally advanced cervical cancer undergoing neoadjuvant chemotherapy. Am J Obstet Gynecol 1991; 164: 631
   PubMed Web of Science ®Google Scholar
• Dnistrian A, Schwartz MK. Lipid-associated sialic acid. Clin Chem News 1985; 11: 10
   Google Scholar
• Schwartz P E, Chambers S K, Chambers JT, et al. Circulating tumor markers in the monitoring of gynecologic malignancies. Cancer 1987; 60: 353
   PubMed Web of Science ®Google Scholar
• Petru E, Sevin B U, Averette HE, et al. Comparison of three tumor markers - CA125, lipid-associated sciatic acid (LSA), and NB/70K - in monitoring ovarian cancer. Gynecol Oncol 1990; 38: 181
   PubMed Web of Science ®Google Scholar
• Gold P, Freedman SO. Demonstration of tumor specific antigens in human colonic carcinomata by immunological tolerance and absorbtion techniques. J Exp Med 1965; 121: 439
   PubMed Web of Science ®Google Scholar
• Heald J, Buckley C H, Fox H. An immunohistochemical study of the distribution of CEA in epithelial tumors of the ovary. J Clin Pathol 1979; 32: 918
   PubMed Web of Science ®Google Scholar
• Stall K E, Martin EW. Plasma carcinoembryonic antigen levels in ovarian cancer patients: A chart review and survey of published data. J Reprod Med 1981; 26: 75
   Web of Science ®Google Scholar
• Bast R C, Klug T L, Schaetzl E, et al. Monitoring human ovarian carcinoma with a combination of CA125, CA19–9 and carcinoembryonic antigen. Am J Obstet Gynecol 1984; 149: 553
   PubMed Web of Science ®Google Scholar
• Cohen C, Shulman G, Budgeon LR. Endocervical and endometrial adenocarcinoma: An immunoperoxidase and histochemical study. Am J Surg Pathol 1982; 6: 151
   PubMed Web of Science ®Google Scholar
• Kjørstad K E, Rjaseter H. Studies on carcinoembryonic antigen levels in patients with adenocarcionoma of the uterus. Cancer 1977; 40: 2953
   PubMed Web of Science ®Google Scholar
• Kjørstad K E, Ørjaseter H. Carcinoembryonic antigen levels in patients with squamous cell carcinoma. Obstet Gynocol 1977; 51: 293
   Web of Science ®Google Scholar
• Bast R C, Klug T L, St John E, et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med 1983; 309: 883
   PubMed Web of Science ®Google Scholar
• Klug T L, Bast R C, Niloff JM, et al. Monoclonal antibody immunoradiometric assay for an antigenic determinant (CA125) associated with human epithelial ovarian carcinoma. Cancer Res 1984; 44: 1048
   PubMed Web of Science ®Google Scholar
• Kabawat S E, Bast RC, Bhan AK, et al. Tissue distribution of a coelomic epithelium related antigen recognized by the monoclonal antibody OC125. Int J Gynecol Pathol 1983; 2: 275
   PubMed Web of Science ®Google Scholar
• Bast R C, Feeney M, Lazarus H, et al. Reactivity of a monoclonal antibody with ovarian carcinoma. J Clin Invest 1981; 68: 1331
   PubMed Web of Science ®Google Scholar
• Westhoff C, Gollub E, Patel J, et al. CA125 in menopausal women. Obstet Gynecol 1990; 76: 428
   PubMed Web of Science ®Google Scholar
• Vergote I B, Børmer O P, Abeler VM. Evaluation of serum CA125 levels in the monitoring of ovarian cancer. Am J Obstet Gynecol 1987; 157: 88
   PubMed Web of Science ®Google Scholar
• Pittaway D E, Fayez JA. Serum CA125 antigen levels increase during menses. Am J Obstet Gynecol 1987; 156: 75
   PubMed Web of Science ®Google Scholar
• Niloff J M, Knapp R C, Schaetz LE, et al. CA125 serum levels in obstetric and gynecologic patients. Obstet Gynecol 1984; 64: 703
   PubMed Web of Science ®Google Scholar
• Vasilev S A, Schlaerth JB, Campeau J, et al. Serum CA125 levels in preoperative evaluation of pelvic masses. Obstet Gynecol 1988; 71: 751
   PubMed Web of Science ®Google Scholar
• Ruibal A, Encabo G, Capdevila JA, et al. CA125 serum levels in patients with liver disease. Med Clin (Barcelona) 1984; 82: 560
   Google Scholar
• Rustin G, Gennings J N, Nelstrop AE, et al. Use of CA125 to predict survival of patients with ovarian carcinoma. J Clin Oncol 1989; 7: 1667
   PubMed Web of Science ®Google Scholar
• Lavin P T, Knapp R C, Malkasian G, et al. CA125 for the monitoring of ovarian carcinoma during primary therapy. Obstet Gynecol 1987; 69: 223
   PubMed Web of Science ®Google Scholar
• Niloff J M, Bast R C, Schaetzl EM, et al. Predictive value of CA125 antigen levels at second look procedures in ovarian cancer. Am J Obstet Gynecol 1985; 148: 1057
   Web of Science ®Google Scholar
• Onsrud M, Vergote I, Moen M. CA125 in peritoneal fluids of healthy women and of patients with ovarian carcinoma. Proc 24th Congr Scand Soc Obstet Gynecol. Trondheim 1988, Abstr 49
   Google Scholar
• Fleuren G J, Nap M, Aalders JG, et al. Explanation of the limited correlation between tumor CA125 content and serum CA125 antigen levels in patients with ovarian tumors. 1987; 60: 2437
   Google Scholar
• Malkasian G D, Knapp R C, Lavin PT, et al. Preoperative evaluation of serum CA125 levels in premenopausal and postmenopausal patients with pelvic masses: discrimination of benign from malignant disease. Am J Obstet Gynecol 1988; 159: 341
   PubMed Web of Science ®Google Scholar
• Jacobs I J, Fay T W, Lower AM, et al. The London Hospital ovarian cancer screeening project. Proc 2nd Meeting Int Gynecol Cancer Soc. Toronto 1989, Abstr 167
   Google Scholar
• Einhorn N, Sjøvall K, Schoenfeld DA, et al. Early detection of ovarian cancer using CA125 radioimmunoassay. Proc ASCO 1990; 607
   Google Scholar
• Altaras M M, Goldberg G L, Levin W, et al. The value of cancer antigen-125 as a tumor marker in malignant germ cell tumors of the ovary. Gynecol Oncol 1985; 25: 150
   Web of Science ®Google Scholar
• Kivinen S, Kuopala T, Leppilampi M, et al. Tumor-associated antigen CA125 before and during treatment of ovarian cancer. Obstet Gynecol 1986; 67: 468
   PubMed Web of Science ®Google Scholar
• Niloff J M, Klug Schaetzl E, et al. Elevation of serum CA125 in carcinoma of the fallopian tube, endometrium, and endocervix. Am J Obstet Gynecol 1984; 148: 1057
   PubMed Web of Science ®Google Scholar
• Patsner B, Or J W, Mann WJ. Use of serum CA125 measurement in posttreatment surveillance of early-stage endometrial carcinoma. Am J Obstet Gynecol 1990; 162: 427
   PubMed Web of Science ®Google Scholar
• Patsner B, Mann WJ. Use of serum CA125 in monitoring patients with uterine sarcoma. A preliminary report. Cancer 1988; 62: 1355
   PubMed Web of Science ®Google Scholar
• Koprowski H, Steplewski Z, Mitchell K, et al. Colorectal carcinoma antigens detected by hybridoma antibodies. Somatic Cell Genet 1979; 5: 957
   PubMedGoogle Scholar
• Hilkens J, Bulis F, Hilgers J, et al. Monoclonal antibodies against human milk-fat globule membranes detecting differention antigens of the mammary gland and its tumor. Int J Cancer 1984; 34: 197
   PubMed Web of Science ®Google Scholar
• Knauf S. Clinical evaluation of ovarian tumor antigen NB/70K: Monoclonal antibody assays for distinguishing ovarian cancer from other gynecologic disease. Am J Obstet Gynecol 1988; 158: 1067
   PubMed Web of Science ®Google Scholar
• Ruoslathi E, Hirai H. Alpha fetoprotein. Scand J Immunol 1978; 8: 3, suppl
   Google Scholar
• Wilkinson E J, Friedrich E G, Hosty T, Alpha-Fetoprotein A. endodermal sinus tumor of the ovary. Am J Obstet Gynecol 1973; 116: 711
   PubMed Web of Science ®Google Scholar
• Van Nagell J R, Donaldson E S, Hanson MB, et al. Biochemical markers in the plasma and tumors of patients with gynecologic malignancies. Cancer 1981; 48: 495
   PubMed Web of Science ®Google Scholar
• Fujii S, Koniski I, Suzuki A, et al. Analysis of serum lactic dehydrogenase levels and its isoenzymes in ovarian dysgerminoma. Gynecol Oncol 1985; 22: 65
   PubMed Web of Science ®Google Scholar
• Fishman W H, Inglis N R, Green S, et al. Immunology and biochemistry of Regan isoenzyme of alkaline phosphatase in human cancer. Nature 1968; 219: 697
   PubMed Web of Science ®Google Scholar
• Vergote I, Onsrud M, Nustad K. Placental alkaline phosphatase as a tumor marker in ovarian cancer. Obstet Gynecol 1987; 69: 228
   PubMed Web of Science ®Google Scholar
• Lappohn R, Burger H, Krans M. Inhibin as a marker for granulosa cell tumors. Proc Symposium Scand Soc Gyncol Oncol, Gothenburg 1991
   Google Scholar